Drug intelligence / Profile preview

SIM0811 (Simcere Pharmaceutical Group)

Development stage: Unknown
Lead developer: Jiangsu Simsheng Pharmaceutical
Modality: Small Molecules
Administration: Intravenous

Overview

SIM0811 is an investigational small-molecule dual-target agent developed by Simcere for the treatment of acute ischemic stroke and thrombosis. It acts as a next-generation plasminogen allosteric activator that enhances the activity of endogenous tissue plasminogen activator (tPA) to accelerate clot breakdown. Additionally, it inhibits soluble epoxide hydrolase (sEH), providing local anti-inflammatory and antioxidant effects at the site of the thrombus. As of early 2026, it is in Phase I clinical development in China to evaluate safety, tolerability, and pharmacokinetics.

Targets

EPHX2 (Soluble epoxide hydrolase)PLG (Plasminogen)

Beyond the preview

Go deeper on SIM0811 (Simcere Pharmaceutical Group).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIM0811 (Simcere Pharmaceutical Group).

Explore the full profile